Scroll To Top
Issue Features

Tips+Tools

Tips+Tools

Cover64_100_8

The next major advance in simplification of treatment could be the approval of antiretrovirals in nanosuspension formulations that release drug molecules slowly, and thus may enable once-monthly'or even less frequent'injectable antiretroviral therapy. A Tibotec Therapeutics experimental nonnuke, rilpivirine (TMC278), is the compound furthest along in the development of this technology, according to research released at the 15th Conference on Retroviruses and Opportunistic Infections.

30 Years of Out100Out / Advocate Magazine - Jonathan Groff and Wayne Brady

From our Sponsors

Most Popular

Latest Stories

HIV Plus Editors

Editor